Gene therapy: Principles and clinical applications in orthopedics

Orthopedics

Volumn 27, Issue 3, 2004, Pages 294-303

  Parikh, Shital N ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; COMPLEMENTARY RNA; CYTOKINE; DNA; DYSTROPHIN; ECDYSONE; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; GLUCOSYLCERAMIDASE; IDURONATE 2 SULFATASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MIFEPRISTONE; NAKED DNA; NEOMYCIN; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; RIBOZYME; RNA; SOMATOMEDIN; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS VECTOR;

ALBERS SCHOENBERG DISEASE; ARTHRITIS; AUTOIMMUNE DISEASE; BONE DEFECT; BONE DYSPLASIA; BONE REMODELING; CHONDRODYSPLASIA; CHONDROPATHY; CLINICAL TRIAL; DNA MODIFICATION; DRUG SAFETY; EHLERS DANLOS SYNDROME; GAUCHER DISEASE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC RECOMBINATION; HUMAN; INTERVERTEBRAL DISK DISEASE; KNEE MENISCUS RUPTURE; LIGAMENT INJURY; MEDICAL RESEARCH; MUCOPOLYSACCHARIDOSIS; MUSCULAR DYSTROPHY; MUSCULOSKELETAL DISEASE; NOMENCLATURE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ORTHOPEDICS; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SPINE FUSION; TENDON INJURY; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

EID: 1642568739     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/0147-7447-20040301-14     Document Type: Review

References (97)

1. Latchman DS. Germline gene therapy? Gene Ther. 1994; 1:277-279.
2. Parens E, Juengst E. Inadvertently crossing the germ line. Science. 2001; 292:397.
3. Anderson WF. Human gene therapy. Science. 1992; 256:8088-813.
4. Anderson WF. Human gene therapy. Nature. 1998; 392:25-30.
5. Anderson WF. Gene therapy for genetic diseases. Hum Gene Ther. 1994;5 :281-282.
6. Herrmann F. Clinical application of gene transfer. J Mol Med. 1996; 74:213-221.
7. Marini JC, Gerber NL. Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy. JAMA. 1997; 277:746-750.
8. Khillan JS, Li SW, Prockop DJ. Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene. Proc Natl Acad Sci U S A. 1994; 91:6298-6302.
9. Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest. 1996; 97:448-454.
10. Grassi G, Forlino A, Marini JC. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res. 1997; 25:3451-3458.
11. Oligino TJ, Yao Q, Ghivizzani SC, Robbins P. Vector systems for gene transfer to joints. Clin Orthop.2000; 379(Suppl):S17-S30.
12. Evans CH, Robbins PD. Possible orthopaedic applications of gene therapy. J Bone Joint Surg Am. 1995; 77:1103-1114.
13. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther. 1998; 80:35-47.
14. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science. 1996; 272:263-267.
15. Buchschacher GL Jr, Panganiban AT. Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol. 1992; 66:2731-2739.
16. Hope MJ, Mui B, Ansell S, Ahkong OF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Mol Membr Biol. 1998; 15:1-14.
17. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW.Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A. 1994; 91:4086-4090.
18. Klein RM, Wolf ED,Wu R, Sanford JC. High-velocity microprojectiles for delivering nucleic acids into living cells. Nature. 1987; 327:70-75.
19. Stephenson J. New method to repair faulty gene stirs interest in chimeraplasty technique. JAMA. 1999; 281:119-121.
20. Wu XS, Liu DP, Liang CC. Prospects of chimeric RNA-DNA oligonucleotides in gene therapy. J Biomed Sci. 2001; 8:439-445.
21. Richard PD, Kren BT, Steer CJ. Gene repair in the new age of gene therapy. Hepatology. 2002; 35:512-518.
22. Challita PM, Kohn DB. Lack of expression from a retroviral vector after trasduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A. 1994; 91:2567-2571.
23. Wang Y, O'Malley BW Jr, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci U S A. 1994; 91:8180-8184.
24. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992; 89:5547-5551.
25. Rivera VM, Clackson T, Natesan S, et al. A humanized system for pharmacologic control of gene expression. Natl Med. 1996; 2:1028-1032.
26. Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 1999; 283:88-91.
27. No D, Yao TP, Evans RM. Ecdysoneinducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A. 1996; 93:3346-3351.
28. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer. J Exp Med. 1992; 176:1125-1135.
29. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science. 1999; 285:2084-2088.
30. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001; 291:1304-1351.
31. McPherson JD, Hillier L, Waterson RH, et al. A physical map of the human genome. Nature. 2001; 409:934-940.
32. Lian JB, Niyibizi C. Gene therapy for genetic diseases of bone. Clin Orthop. 2000; 379(Suppl):S159-S163.
33. Tsuji S, Choudary PV, Martin BM, Winfield S, Barranger JA, Ginns EI. Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J Biol Chem. 1986; 261:50-53.
34. Sorge J, Kuhl W, West C, Beutler E. Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A. 1987; 84:906-909.
35. Nimgaonkar MT, Bahnson AB, Boggs SS, Ball ED, Barranger JA. Transduction of mobilized peripheral blood CD34+ cells with the glucocerebrosidase cDNA. Gene Ther. 1994; 1:201-207.
36. Choudary PV, Barranger JA, Tsuji S, et al. Retrovirus-mediated transfer of the human glucoscerebrosidase gene to Gauchre fibroblasts. Mol Biol Med. 1986; 293-299.
37. Sakamoto M, Yuasa K, Yoshimura M, et al. Micor-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun. 2002; 293: 1265-1272.
38. Bertoni c, Rando TA. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum Gene. Ther. 2002; 13:707-718.
39. De Angelis FG, Sthandier O, Berarducci B, et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc Natl Acad Sci U S A 2002; 99:9456-9461.
40. Levy RJ, Goldstein Sa, Bonadio J. Gene therapy for tissue repair and regeneration. Adv Drug Deliv Rev. 1998; 33:53-69.
41. Lieberman J, Ghivizzani S, Evans C. Gene transfer approaches to the healing of bone and cartilage. Mol Ther 2002; 6:141-147.
42. Niyibizi C, Baltzer A, Lattermann C, et al. Potential role for gene therapy in the enhancement of fracture healing. Clin Orthop. 1998; 355(Suppl):S148-S153.
43. Liebermann JR, Daluiski A, Stevenson S, et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bonemarrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg
44. Liebermann JR, Le LQ, Wu L, et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998; 16:330-339.
45. Oakes DA, Lieberman JR. Osteoinductive applications of regional gene therapy: Ex vivo gene transfer. Clin Orthop. 2002; 379(Suppl):S101-S112.
46. Breitbart AS, Grande DA, Mason JM, Barcia M, James T, Grant RT. Gene-enhanced tissue engineering: Applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg. 1999; 42:488-495.
47. Gazit D, Turgeman G, Kelley P, et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J Gene Med 1999; 1:121-133.
48. Rutherford RB, Moalli M, Franceschi RT, Wang D, Gu K, Krebsbach PH. Bone morphogenetic protein-transduced human fibroblasts convert convert to osteoblasts and form bone in vivo. Tissue Eng. 2002; 8:441-452.
49. Krebsbach PH, Gu K, Franceschi RT, Rutherford RB. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther. 2000; 11:1201-1210.
50. Lee JY, Musgrave D, Pelinkovic D, et al. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. J Bone Joint Surg Am. 2001; 83:1032-1039.
51. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 2001; 7:211-228.
52. Baltzer AW, Lattermann C, Whalen JD, et al. Potential role of direct adenoviral gene transfer in enhancing fracture repair. Clin Orthop. 2000; 379(Suppl):S120-S125.
53. Fang J, Zhu YY, Smiley E, et a. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci U S A. 1996; 93:5753-5758.
54. Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration. Nat Med. 1999; 5:753-759.
55. Ghivizzani SC, Oligino TJ, Glorioso JC, Robbins PD, Evans CH. Gene therapy approaches for treating rheumatoid arthritis. Clin Orthop. 2002; 379(Suppl):S288-S299.
56. Fernandes JC, Martel-Pelletier J, Pelletier JP. Gene therapy for osteoarthritis: New perspectives for the twenty-first century. Clin Orthop. 2000; 379(Suppl):S262-S272.
57. Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH. Gene transfer to synoviocytes: Prospects for gene treatment of arthritis. DNA Cell Biol. 1992; 11: 227-231.
58. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997; 40:1012-1019.
59. Frisbie DD, McIlwraith CW. Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clin Orthop. 2000; 379(Suppl):S273-S287.
60. Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: Prevention of osteoarthritis progression. Am J Pathol 1999; 154:1159-1169.
61. Tomita T, Hashimoto H, Tomita N, et al. In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes. Arthritis Rheum. 1997; 40:901-906.
62. Arai Y, Kubo T, Kobayashi K, et al. Adenovirus vector-mediated gene transduction to chondrocytes: In vitro evaluation of therapeutic efficacy of transforming growth factor-beta 1 and heat shock protein 70 gene transduction. J Rheumatol. 1997; 24:1787-1795.
63. Evans CH, Ghivizzani SC, Kang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum. 1999; 42:1-16.
64. Evans CH, Robbins PD. Potential treatment of osteoarthritis by gene therapy. Rheum Dis Clin North Am. 1999; 25:333-344.
65. Evans CH, Ghivizzani SC, Herndon JH, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop. 2000; 379 (Suppl): S300-S307.
66. Sant SM, Suarez TM, Moalli MR, et al. Molecular lysis of synovial lining cells by in vivo heroes simplex virus-thymidine kinase gene transfer. Hum Gene Ther. 1998; 9:2735-2743.
67. Goossens PH, Schouten GJ, 'tHart BA, et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum Gene Ther. 1999; 10:1139-1149.
68. Frank CB. Ligament healing: Current knowlege and clinical applications. J Am Acad Orthop Surg. 1996; 4:74-83.
69. Gerich TG, Kang R, Fu FH, Robbins PD, Evans CH. Gene transfer to the patellar tendon. Knee Surg Sports Traumatol Arthrosc. 1997; 5:118-123.
70. Hildebrand KA, Deie M, Allen CR, et al. Early expression of marker genes in the rabbit medial collateral and anterior cruciate ligaments: The use of different viral vectors and the effects of injury. J Orthop Res. 1999; 17:37-42.
71. Hart DA, Nakamura N, Marchuk L, et al. Complexity of determining cause and effect in vivo after antisense gene therapy. Clin Orthop. 2000; 379(Suppl):S242-S251.
72. Nakamura N, Hart DA, Boorman RS, et al. Decorin antisense gene therapy improves functional healing of early rabbit ligament scar with enhanced collagen fibrillogenesis in vivo. J Orthop Res. 2000; 18:517-523.
73. Lou J. In vivo gene transfer into tendon by recombinant adenovirus. Clin Orthop. 2000; 379(Suppl):S252-S255.
74. Lou J, Tu Y, Burns M, Silva MJ, Manske P. BMP-12 gene transfer augmentation of lacerated tendon repair. J Orthop Res. 2001; 19:1199-1202.
75. Helm GA, Li JZ, Alden TD, et al. A lignt and electron microscopic study of ectopic tendon and ligament formation induced by bone morphogenetic protein-13 adenoviral gene therapy. J Neurosurg. 2001; 95:298-307.
76. Martinek V, Latterman C, Usas A, et al. Enchancement of tendon-bone integration of anterior cruciate ligament grafts with bone morphogenetic protein-2 gene transfer: A histological and biomechanical study. J Bone Joint Surg Am. 2002; 84:1123-1131.
77. Boden SD, Hair GA, Viggeswarapu M, Liu Y, Titus L. Gene therapy for spine fusion. Clin Orthop. 2000; 379(Suppl):S225-S233.
78. Boden SD, Titus L. Hair G, et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine. 1998; 23:2486-2492.
79. Boden SD, Liu Y, Hair GA, et al. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology. 1998; 139:5125-5134.
80. Boden SD. Bioactive factors for bone tissue engineeting. Clin Orthop. 1999; 367(Suppl): S84-S94.
81. Viggeswarapu M, Boden SD, Liu Y, et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J Bone Joint Surg Am. 2001; 83:364-376.
82. Nishida K, Gilbertson LG, Robbins PD, Evans CH, Kand JD. Potential applications of gene therapy to the treatment of intervertebral disc disorders. Clin Orthop. 2000; 379(Suppl):S234-S241.
83. Thompson JP, Oegema TR Jr, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine. 1991; 16:253-260.
84. Nishida K, Kang JD, Suh JK, Robbins PD, Evans CH, Gilbertson LG. Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration. Spine. 1998; 23:2437-2442.
85. Nishida K, Kang JD, Gilbertson LG, et al. Modulation of the biologic activity of the rabbit interbertebral disc by gene therapy: An in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine. 1999; 24:2419-2425.
86. Wehling P, Schulitz KP, Robbins PD, Evans CH, Reinecke JA. Transfer of genes to chondrocytic cells of the lumbar spine. Proposal for a treatment strategy of spinal disorders by local gene therapy. Spine. 1997; 22:1092-1097.
87. Onyia JE, Clapp DW, Long H, Hock JM. Osteoprogenitor cells as targets for ex vivo gene transfer. J Bone Miner Res. 1998; 13: 20-30.
88. Yoo JU, Mandell I, Angele P, Johnstone B. Chondrogenitor cells and gene therapy. Clin Orthop. 2000; 379(Suppl):S164-S170.
89. Sellers RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Joint Surg Am. 1997; 79:1452-1463.
90. Mason JM, Breibart AS, Barcia M, Porti D, Pergolizzi RG, Grande DA. Cartilage and bone regeneration using gene-enchanced tissue engineering. Clin Orthop. 2000; 379(Suppl):S171-S178.
91. Nixon AJ, Brower-Toland BD, Bent SJ, et al. Insulinlike growth factor-I gene therapy applications for cartilage repair. Clin Orthop. 2000; 379(Suppl):S201-S213.
92. Goto H, Shuler FD, Lamsam C, et al. Transfer of lacZ marker gene to the meniscus. J Bone Joint Surg Am. 1999; 81:918-925.
93. Goto H, Shuler FD, Niyibizi C, Fu FH, Robbins PD, Evans CH. Gene therapy for meniscal injury: Enhanced synthesis of proteoglycan and collagen by meniscal cells transduces with a TGFbeta(1)gene. Osteoarthritis Cartilage. 2000; 8:266-271.
94. Hidaka C, Ibarra C, Hannafin JA, et al. Formation of vascularized meniscal tissue by combining gene therapy with tissue engineering. Tissue Eng. 20002; 8:93-105.
95. Baltzer AW, Whalen JD, Wooley P, et al. Gene therapy for osteoporosis: Evaluation in a murine ovariectomy model. Gene Ther. 2001; 8:1770-1776.
96. Bolon B, Carter C, Daris M, et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther. 2001; 3:197-205.
97. Ulrich-Vinther M, Carmody EE, Goater JJ, Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am. 2002; 84:1405-1412.